Statera Biopharma Submits Phase 3 Clinical Trial Protocol to FDA for Investigational Treatment of Pediatric Crohn’s Disease
Company developing STAT-201 as a novel therapy for immune modulation in treating pediatric patients with Crohn’s DiseaseFORT COLLINS, Colo., Dec....